Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Batist

Showing results (11-20 of 165) with videos related to

Pageof 17
Sort By:
Molecular Pharmacology|January 19, 2007
Structure-based identification of novel human gamma-glutamylcysteine synthetase inhibitorsDavid Hamilton, Jian Hui Wu, Gerald Batist
Cancer Treatment and Research|December 17, 2002
The glutathione system in alkylator resistanceDavid Hamilton, Nasser Fotouhi-Ardakani, Gerald Batist
American Journal of Translational Research|November 3, 2011
Emerging drug discovery approaches for selective targeting of "precursor" metastatic breast cancer cells: highlights and perspectivesMoulay Aalaoui-Jamali, Krikor Bijian, Gerald Batist
Journal of Proteome Research|January 13, 2025
Characterization of 53 Multiplexed Targeted Proteomics Assays for Verification Studies in Cancer Cell LinesConstance A Sobsey, Gerald Batist, Christoph H Borchers
Current Oncology (Toronto, Ont.)|February 24, 2022
Treatment Access, Health Economics, and the Wave of a Magic WandDavid J Stewart, John-Peter Bradford, Gerald Batist
Molecular Pharmacology|July 19, 2003
Oltipraz is a bifunctional inducer activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic responsive elementWeimin Miao, Lianggao Hu, Mustapha Kandouz, et al.
Journal of Oncology Practice|May 5, 2017
Toward Implementing Patient Flow in a Cancer Treatment Center to Reduce Patient Waiting Time and Improve EfficiencySamuel Suss, Nadia Bhuiyan, Kudret Demirli, et al.
Current Opinion in Oncology|February 24, 2010
The biology behind prognostic factors of cutaneous melanomaAlan Spatz, Gerald Batist, Alexander M M Eggermont
Cancer Letters|January 3, 2006
The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity actionKhadidja Haïdara, Lolita Zamir, Qui-Wen Shi, et al.
Bioorganic & Medicinal Chemistry Letters|January 14, 2009
Syntheses and potential anti-prostate cancer activities of ionone-based chalconesJinming Zhou, Guoyan Geng, Gerald Batist, et al.
Pageof 17

Showing results (11-20 of 165) with videos related to

Sort By:
Pageof 17
Molecular Pharmacology|January 19, 2007
Structure-based identification of novel human gamma-glutamylcysteine synthetase inhibitorsDavid Hamilton, Jian Hui Wu, Gerald Batist
Cancer Treatment and Research|December 17, 2002
The glutathione system in alkylator resistanceDavid Hamilton, Nasser Fotouhi-Ardakani, Gerald Batist
American Journal of Translational Research|November 3, 2011
Emerging drug discovery approaches for selective targeting of "precursor" metastatic breast cancer cells: highlights and perspectivesMoulay Aalaoui-Jamali, Krikor Bijian, Gerald Batist
Journal of Proteome Research|January 13, 2025
Characterization of 53 Multiplexed Targeted Proteomics Assays for Verification Studies in Cancer Cell LinesConstance A Sobsey, Gerald Batist, Christoph H Borchers
Current Oncology (Toronto, Ont.)|February 24, 2022
Treatment Access, Health Economics, and the Wave of a Magic WandDavid J Stewart, John-Peter Bradford, Gerald Batist
Molecular Pharmacology|July 19, 2003
Oltipraz is a bifunctional inducer activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic responsive elementWeimin Miao, Lianggao Hu, Mustapha Kandouz, et al.
Journal of Oncology Practice|May 5, 2017
Toward Implementing Patient Flow in a Cancer Treatment Center to Reduce Patient Waiting Time and Improve EfficiencySamuel Suss, Nadia Bhuiyan, Kudret Demirli, et al.
Current Opinion in Oncology|February 24, 2010
The biology behind prognostic factors of cutaneous melanomaAlan Spatz, Gerald Batist, Alexander M M Eggermont
Cancer Letters|January 3, 2006
The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity actionKhadidja Haïdara, Lolita Zamir, Qui-Wen Shi, et al.
Bioorganic & Medicinal Chemistry Letters|January 14, 2009
Syntheses and potential anti-prostate cancer activities of ionone-based chalconesJinming Zhou, Guoyan Geng, Gerald Batist, et al.
Pageof 17